TANZISERTIB

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H23F3N6O2
Molecular Weight	448.4415
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@H]1CC[C@@H](CC1)NC2=NC3=C(C=N2)N=C(NC4=C(F)C=C(F)C=C4F)N3[C@H]5CCOC5

InChI

InChIKey=IBGLGMOPHJQDJB-IHRRRGAJSA-N

InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12-,13-,14-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C21H23F3N6O2
Molecular Weight	448.4415
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22244937
Curator's Comment: Description was created based on several sources, including http://www.pharmacodia.com/yaodu/html/v1/chemicals/5ac743bb07d7ade910de883559891e70.html http://www.apexbt.com/cc-930.html

Tanzisertib (CC-930) is a potent and selective inhibitor of JNK1/JNK2/JNK3 with IC50 values of 61 nM, 7 nM and 6 nM respectively. Tanzisertib had been in phase II clinical trials for the treatment of idiopathic pulmonary fibrosis and discoid lupus erythematosus. But this research was discontinued in 2012. In 2011, the compound was granted orphan drug designation in the U.S. and the E.U. for the treatment of idiopathic pulmonary fibrosis. The compound was co-developed by Celgene and Ligand.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
c-Jun N-terminal kinase 1 8 Target ID: CHEMBL2276 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22244937	Inhibitor 8504	61.0 nM [IC50]
c-Jun N-terminal kinase 2 4 Target ID: CHEMBL4179 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22244937	Inhibitor 8504	7.0 nM [IC50]
c-Jun N-terminal kinase 3 5 Target ID: CHEMBL2637 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22244937	Inhibitor 8504	6.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Discoid lupus erythematosus 1 Sources: https://clinicaltrials.gov/ct2/show/NCT01466725	Primary		Phase II 1147	Unknown Approved Use Unknown
Idiopathic pulmonary fibrosis 10 Sources: https://clinicaltrials.gov/ct2/show/NCT01203943	Primary		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
1505 ng × eq/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25482583	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		TANZISERTIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
15827 ng × eq × h/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25482583	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		TANZISERTIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
13 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25482583	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		TANZISERTIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00GUJ0	https://www.1pchem.com/search?query=1P00GUJ0
Compound Cloud	11597537
eMolecules	275090529	https://orderbb.emolecules.com/search/#?query=275090529
eMolecules	301145712	https://orderbb.emolecules.com/search/#?query=301145712
Hairui	HR116738	http://www.hairuichem.com/en/product/search.do?q=HR116738
KeyOrganics	AS-55882	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-55882
MolPort	MolPort-046-702-195	https://www.molport.com/shop/molecule-link/MolPort-046-702-195
Selleck Chemicals	S8490	http://www.selleckchem.com/search.html?searchDTO.searchParam=S8490

PubMed

Title	Date	PubMed
Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans.	2015-05	25482583
In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism.	2015	25475995

Patents

Sample Use Guides

In Vivo Use Guide

25 mg daily for 4 weeks 50 mg once daily for 4 weeks 100 mg daily for 6 weeks

Route of Administration: Oral

In Vitro Use Guide

1-2 uM Tanzisertib (CC-930) blocked apoptosis and necrosis of Jnk1(-/-) and Tlr4(-/-) mouse hepatocytes.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:37:44 GMT 2025` Edited by `admin` on `Mon Mar 31 18:37:44 GMT 2025`
Record UNII	M5O06306UO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TANZISERTIB

Official Name

English

CC-930

Preferred Name

English

tanzisertib [INN]

Common Name

English

TRANS-4-((9-((3S)-TETRAHYDROFURAN-3-YL)-8-((2,4,6-TRIFLUOROPHENYL)AMINO)-9H-PURIN-2- YL)AMINO)CYCLOHEXANOL

Systematic Name

English

JNK930

Code

English

JNK-930

Code

English

TANZISERTIB [USAN]

Common Name

English

CYCLOHEXANOL, 4-((9-((3S)-TETRAHYDRO-3-FURANYL)-8-((2,4,6-TRIFLUOROPHENYL)AMINO)-9H-PURIN-2-YL)AMINO)-, TRANS-

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

348911